Abstract
In this review, we will briefly introduce preventive strategies represented by selected plants which are also popularly used by different traditional medicines and have scientific evidences of possible alternative therapeutic value for neuroprotection. Among these commonly used in most traditional medicines of China and India are Gingko biloba, Panax ginseng, Curcuma longa, Withania somnifera (WS) etc. In addition, scientific evidences of usefulness of Vitis vinifera (Grapes) as red wine, Coffee sp and Camelia sinensis (Tea) will be discussed. Here, we will also discuss in detail the possible use of WS as potential candidate for treatment of AD. Clinical trials and animal research supported the use of WS for treatment of anxiety, cognitive and neurological disorders, senile dementia, Alzheimer’s (AD) and Parkinson’s disease (PD), and as antioxidant and anti-inflammatory agent. This might be important in suggesting therapeutic implications of WS in neurodegenerative disorders.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aggarwal BB, Harikumar KB (2008) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41:40–59
Agorogiannis EI, Agorogiannis GI, Papadimitriou A, Hadjigeorgiou GM (2004) Protein misfolding in neurodegenerative diseases. Neuropathol Appl Neurobiol 30:215–224
Ascherio A, Zhang SM, Hernan MA (2001) Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 50:56–63
Barja G (2004) Free radicals and aging.Trends Neurosci 23:209–216
Bastianetto S, Zhang WH, Quirion R (2000) Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide toxicity in cultured hippocampal neurons. Br J Pharmacol 131:711–720
Blanchet, J. Longpré, F., Bureau, G., Morisette, M.; DiPaolo, T., Bronchti, G., Martinoli, M.G. (2008) Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Progr Neuropsychopharmacol Biol Psych 32:1243–1250
Birks J, Grimley EJ (2009) Ginkgo biloba for cognitive impairment and dementia.Cochrane Database Syst Rev 1:CD003120
Bhattacharya SK, Muruganandam AV (2003) Adaptogenic activity of Withania somnifera: an experimental study using a rat model of chronic stress. Pharmacol Biochem Behav 75:547–55
Bhattacharya A, Ramanathan M, Ghosal S et al. (2000) Effect of Withania somnifera glycowithanolites on iron induced hepatotoxocity in rats. Phytother Res 14:568–570
Bhatnagar M (2009) Novel leads from herbal drugs for neurodegenerative diseases. In: Ramawat KG (ed) Herbal drugs: ethanomedicine to modern medicine. Springer, Berlin, pp 221–238
Bhatnagar M, Sisodia SS, Bhatnagar R (2006) Antiulcer and antioxidant activity of Asparagus racemosus WIILD and Withania somnifera DUNN in rats. Ann N Y Acad Sci 1056:261–278
Bhatnagar M, Sharma D, Salvi M (2009) Neuroprotective effects of Withania somnifera dunal.: a possible mechanism. Neurochem Res 34:1975–1983
Campbell S, Macqueen G (2004) The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 29:417–426
Cauli O, Morelli M (2005) Caffeine and the dopaminergic system. Behav Pharmacol 16:63–77
Chowdhry MT, Yousuf S, Nawajz SA, Ahmed S, Rahman AU (2004) Cholinesterase inhibiting withanolides from Withania somnifera. Chem Pharm Bull 52:1358–1361
Chandrasekaran K, Mehrabian Z, Spinnewyn B, Chinopoulos C, Drieu K, Fiskum G (2003) Neuroprotective effects of bilobalide, a component of Ginkgo biloba extract (EGb 761) in global brain ischemia and in excitotoxicity-induced neuronal death. Pharmacopsychiatry 36:89–94
Chen F, Eckman EA, Eckman CB (2006) Reductions in levels of the Alzheimer’s amyloid β peptide after oral administration of ginsenosides. FASEB J 20:1269–1271
Coimbra S, Castro E, Rocha-Pereira P, Rebelo I, Rocha S, Santos-Silva A (2006) The effect of green tea in oxidative stress. Clin Nutr 25:790–796
Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA (2004) NSAID and antioxidant prevention of Alzheimer’s disease: lessons from in vitro and animal models. Ann NY Acad Sci 1035:68–84
DeKosky ST, Fitzpatrick A, Ives DG, Saxton J, Williamson J, Lopez OL, Burke G, Fried L, Kuller LH, Robbins J, Tracy R, Woolard N, Dunn L, Kronmal R, Nahin R, Furberg C (2006) The Ginkgo evaluation of memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials 27:238–253
De Oliveira RMW, Deakin JF, Guimaraes FS (2000) Neuronal nitric oxide synthase (NOS) expression in the hippocampal formation of patients with schizophrenia and affective disorder. J Psychopharmacol 14:8
Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384–386
Echeverry MB, Guimarães FS, Del Bel EA (2004) Acute and delayed restraint stress-induced changes in nitric oxide producing neurons in limbic regions. Neuroscience 125:981–993
Ganzera M, Choudhary MI, Khan IA (2003) Quantitative HPLC analysis of withanolides in Withania somnifera. Fitoterapia 74:68–76
Gupta GL, Rana AC (2007) Withania somnifera (Ashwagandha): a review. Pharmacogn Rev 1:129–136
Gupta SK, Dua A, Vohra BP (2003) Withania somnifera (Ashwagandha) attenuates antioxidant defense in aged spinal cord and inhibits copper induced lipid peroxidation and protein oxidative modifications. Drug Metabol Drug Interact 19:211–222
Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY, Kim M (2008) An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer’s disease. Eur J Neurol 15:865–868
Harwey BH, Retief R, Korff A et al. (2006) Increased hippocampal nitric oxide synthase activity and stress responsiveness after imipramine discontinuation: role of 5HT 2A/C receptors. Metab Brain Dis 21:211–220
Haque AM, Hashimoto M, Katakura M, Tanabe Y, Hara Y, Shido O (2006) Long-term administration of green tea catechins improves spatial cognition learning ability in rats. J Nut 136:1043–1047
Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60:1119–1122
Jain S, Shukla SD, Sharma K et al. (2001) Neuroprotective Effects of Withania somnifera Dunn in hippocampal sub-regions of female albino rat. Phytother Res 15:544–548
Jenner P (2004) Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson’s disease. Neurology 63:13–22
Joca SR, Guimaraes FS (2006) Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant like effects. Psychopharmacology (Berl) 185:298–305
Joo SS, Yoo YM, Ahn BW, Nam SY, Kim YB, Hwang KW, Lee DI (2008) Prevention of inflammation-mediated neurotoxicity by Rg3 and its role in microglial activation. Biol Pharm Bull 31:1392–1396
Kluchova D, Schmidtova K, Rybarova S, Lovasova K, Pomfy M, Prosbova T, Vatlak A (2000) Partial colocalization of NADPH-diphorase and acetylcholine esterase positivity in spinal cord neurons. Physiol Res 49:151–155
Khokhar S, Magnusdottir SG (2002) Total phenol, catachin and caffeine content of teas commonly consumed in the United Kingdom. J Agric Food Chem 50:565–570
Kuriyama S, Hozawa A, Ohmori K, Shimazu T, Matsui T, Ebihara S, Awata S, Nagatomi R, Arai H, Tsuji I (2006) Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. Am J Clin Nutr 83:355–361
Law A, Gauthier S, Quirion R (2001a) Say NO to Alzheimer’s disease: putative links between nitric oxide and dementia of Alzheimer’s type. Brain Res Rev 1:73–96
Law A, Gauthier S, Quirion R (2001b) Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthatase inhibitors, nitric oxide scavengers and antioxidant against beta amyloid activity. Br J Pharmacol 133:1114–1124
Lewitt PA (2008) Levodopa for the treatment of Parkinson’s disease. N Engl J Med 359:2468–2476
Linn GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21:8370–8377
Luo Y, Smith J, Paramasivam V, Burdick A, Curry K, Buford J, Khan I, Netzer W, Xu H, Butko P (2002) Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci U S A 99:12197–12202
Maia L, de Mendonca A (2002) Does caffeine intake protect from Alzheimer’s disease? Eur J Neurol 9:377–382
Mandel S, Youdim MB (2004) Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic Biol Med 37:304–317
Masood A, Banerji B, Vijayan VK et al. (2004) Pharmacological and biochemical studies on the possible role of nitric oxide in stress adaptation in rats. Eur J Pharmacol 493:1111–1115
Matsushita H, Takeuchi Y, Kawata M et al. (2001) Distribution of NADPH Diaphorase positive neurons in the mouse brain: differences from previous finding in the rat brain and comparison with the distribution of serotonergic neurons. Acta Histochem Cytochem 34:235–257
Mclatchey WC, Mahady G, Bennett BC, Shiels L, Savo V (2009) Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources. Pharmacol Therapeut 12:239–254
McEwen BS, Magarinos AM, Reagan LP (2002) Structural plasticity and tianeptine: cellular and molecular targets. Eur Psychiatry 17:318–330
Mcleod TM, Lopez-Feguero AL, Lopez-Feguero MO (2001) Nitric oxide, stress and depression. Psychopharmacol Bull 35:24–41
Melo JB, Agostinho P, Oliveira CR (2003) Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta peptide. Neurosci Res 45:117–127
Menken M, Munsat TL, Toole JF (2000) The global burden of disease study: implications for neurology. Arch Neuro 57:418–420
Mishra LC, Singh BB, Dagenais S (2000) Scientific basis for therapeutic use of Withania somnifera (ashwagandha): a review.Altern Med Rev 5:334–346
Nikam S, Nikam P, Ahaley SK, Sontakke AV (2009a) Oxidative stress in Parkinson’s disease. Indian J Clin Biochem 24:98–101
Nikam S, Nikam P, Ahaley SK (2009b) Role of free radical and antioxidant imbalance in pathogenesis of Parkinson’s disease. Biomed Res 20:55–58
Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of Parkinson disease. Neurology 72:1–13.
Okere CO, Waterhouse BD (2006) A cute restraint increases NADPH-diaphorase staining in distinct subregions of the rat dorsal raphe nucleus: implications for raphe serotonergic and nitrergic transmission. Brain Res 1119:174–181
Persson CM, Wallin AK, Levander S, Minthon L (2009) Changes in cognitive domains during three years in patients with Alzheimer’s disease treated with donepezil. BMC Neurol 9:7
Pervaiz S (2003) Resveratrol: from grapevines to mammalian biology. FASEB J 17:1975–1985
Pinder RM (2009) Does wine prevents dementia? Int J Wine Res 1:41–152
Prakash D, Suri S, Upadhyay G et al. (2007) Total phenol, antioxidant and free radical scavenging activities of some medicinal plants. Int J Food Sci Nutr 58:18–28
Prast H, Philippu A (2001) Nitric oxide as modulator of neuronal function. Prog Neurobiol 64:51–68
Prior RL, Cao G (2000) Antioxidant phytochemicals in fruits and vegetables: diet and health implications. Hortic Sci 35:588–592
Rivière C, Richard T, Vitrac X, Mérillon JM, Valls J, Monti JP (2008) New polyphenols active on β -amyloid aggregation. Bioorg Medic Chem Lett 18:828–831
Rudakewich M, Ba F, Benishin CG (2001) Neurotrophic and neuroprotective actions of ginsenoside Rb1 and Rg1. Planta Med 67:533–537
Schliebs R, Liebmann A, Bhattacharya SK et al. (1997) Systemic administration of defined extracts from Withania somnifera (Indian ginseng) and Shilajit differentially affects cholinergic but not glutamatergic and gabaergic markers in rat brain. Neurochem Int 30:181–190
Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766
Shastry BS (2003) Neurodegenerative disorders of protein aggregation. Neurochem Int 43:1–7
Strimpakos AS, Sharma RA (2008) Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10:511–545
Suk K (2005) Regulation of neuroinflammation by herbal medicine and its implications for neurodegenerative diseases: a focus on traditional medicines and flavonoids. Neurosignals 14:23–33
Talesa VN (2001) Acetylcholineste in Alzheimer’s disease. Mech Aging Dev 122:1961–1969
Terriot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317–324
Uno K, Hasegawa K, Naiki H, Yamada M (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res 75:742–750
Van Kampen J, Robertson H, Hagg T, Drobitch R (2003) Neuroprotective actions of the ginseng extracts G115 in two rodent models of Parkinson’s disease. Exp Neurol 184:521–529
Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H (2006) The GuidAge study.Methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761® for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 67:6–11
Vinutha B, Prasantha HD, Salma K, Sreej SL, Pratiti D, Padmaja R, Radhika S, Amit A, Warulu KV, Deepak M (2007) Screening of selected Indian medicinal plants for acetylcholinesterase inhibitory activity. J Ethanopharmacol 109:359–363
Weinreb O, Mandel S, Amit T, Youdim MB (2004) Neurological mechanisms of green tea polyphenols in Alzheimer’s and Parkinson’s diseases. J Nutr Biochem 15:506–516
Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM (2005) Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280:5892–5901
Yao Z, Drieu K, Papadopoulos V (2001) The Ginkgo biloba extract EGb761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid- derived diffusible neurotoxic ligands. Brain Res 889:181–190
Yuan H, Zheng JC, Liu P, Zhang SF, Xu JY, Bai LM (2007) Pathogenesis of Parkinson’s disease: oxidative stress, environmental impact factors and inflammatory processes. Neurosci Bull 23:125–130
Yun TK (2001) Brief introduction of Panax ginseng. J Korean Med Sci 16:3–5
Zhang LJ, Wu CF, Meng XL, Yuan D, Cai XD, Wang QL (2008) Comparison of inhibitory potency of three different curcuminoid pigments on nitric oxide and tumor necrosis factor production of rat primary microglia induced by lipopolysaccharide. Neurosci Lett 447:48–53
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Bhatnagar, M., Jain, A., Jaiswal, N., Sharma, C., Suvalka, P. (2012). Understanding Mechanism of Action of Herbal Drugs in Age Related Degenerative Brain Disorders. In: Thakur, M., Rattan, S. (eds) Brain Aging and Therapeutic Interventions. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5237-5_11
Download citation
DOI: https://doi.org/10.1007/978-94-007-5237-5_11
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-5236-8
Online ISBN: 978-94-007-5237-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)